<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424239</url>
  </required_header>
  <id_info>
    <org_study_id>2017P002081</org_study_id>
    <nct_id>NCT03424239</nct_id>
  </id_info>
  <brief_title>Pilot Study for Zoledronic Acid to Prevent Bone Loss After RYGB</brief_title>
  <official_title>Pilot Study for Zoledronic Acid to Prevent High-Turnover Bone Loss After Roux-en-Y Gastric Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs
      after Roux-en-Y Gastric Bypass (RYGB) surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are evaluating the ability of a single dose of zoledronic acid given before
      RYGB to improve bone outcomes after surgery. The investigators have previously shown that
      RYGB has negative effects on skeletal health. The purpose of this study is to prevent the
      bone loss that occurs in adults who have chosen to undergo RYGB. Subjects will be randomized
      to receive either zoledronic acid or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Half of the participants will receive zoledronic acid and half of the participants will receive placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The Data Safety Monitoring Board will be unmasked, but all other parties involved will be masked to treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum CTX</measure>
    <time_frame>6 months</time_frame>
    <description>The primary aim of this study is to determine the postoperative changes in serum markers of bone turnover after a preoperative infusion of zoledronic acid versus placebo. Serum C-terminal telopeptide of type 1 collagen (CTX) is marker of bone resorption.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density by DXA</measure>
    <time_frame>6 months</time_frame>
    <description>Early changes in areal bone mineral density will be measured at the hip and spine by Dual-energy X-ray Absorptiometry (DXA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density by QCT</measure>
    <time_frame>6 months</time_frame>
    <description>Early changes in volumetric bone mineral density will be measured at the spine by Quantitative Computed Tomography (QCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 months</time_frame>
    <description>Hypocalcemia, if detected, will be graded according to common terminology for adverse event criteria (CTCAE v.4).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <arm_group>
    <arm_group_label>Drug: Zoledronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive zoledronic acid (5mg), administered as an intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive sterile free water for injection, administered as an intravenous infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>5mg zoledronic acid</description>
    <arm_group_label>Drug: Zoledronic Acid</arm_group_label>
    <other_name>NDC 25021-830-82</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>sterile free water for injection</description>
    <arm_group_label>Drug: Placebos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men must be age ≥ 50

          -  Women must be postmenopausal

          -  Planning to receive RYGB surgery

        Exclusion Criteria:

          -  Age &lt; 21

          -  Prior bariatric surgery

          -  Weight ≥ 400 lbs

          -  Liver or renal disease

          -  Hypercalcemia, hypocalcemia, or hypomagnesemia

          -  Serum 25-OH vitamin D &lt; 20 ng/mL

          -  History of bone-modifying disorders

          -  Use of bone-active medications

          -  Known sensitivity to bisphosphonates

          -  Extensive dental work involving extraction or dental implant within the past 2 months
             or planned in the upcoming 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine W Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katie Lindeman</last_name>
    <phone>617-724-3255</phone>
    <email>klindeman@mgh.harvard.edu</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elaine W. Yu</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Roux-en-Y gastric bypass</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

